Premium
PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer
Author(s) -
Wang Chao,
Feng Yaping,
Zhang Chengyue,
Cheng David,
Wu Renyi,
Yang Yuqing,
Sargsyan Davit,
Kumar Dibyendu,
Kong AhNg
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201901205rr
Subject(s) - pten , transcriptome , dna methylation , prostate cancer , cancer research , biology , cancer , prostate , dna , computational biology , genetics , gene , gene expression , pi3k/akt/mtor pathway , apoptosis
Abstract Phosphatase and tensin homolog located on chromosome 10 (PTEN) is a tumor suppressor gene and one of the most frequently mutated/deleted genes in human prostate cancer (PCa). However, how PTEN deletion would impact the epigenome and transcriptome alterations remain unknown. This hypothesis was tested in a prostate‐specific PTEN−/− (KO) mouse prostatic adenocarcinoma model through DNA methyl‐Seq and RNA‐Seq analyses. Examination of cancer genomic datasets revealed that PTEN is expressed at lower levels in PTEN‐deleted tumor samples than in normal solid tissue samples. Methylome and transcriptome profiling identified several inflammatory responses and immune response signaling pathways, including NF‐kB signaling, IL‐6 signaling, LPS/IL‐1‐mediated inhibition of RXR Function, PI3K in B lymphocytes, iCOS‐iCOSL in T helper cells, and the role of NFAT in regulating the immune response, were affected by PTEN deletion. Importantly, a small subset of genes that showed DNA hypermethylation or hypomethylation was correlated with decreased or increased gene expression including CXCL1. quantitative polymerase chain reaction analyses of representative genes validated the RNA‐Seq results. Histopathological examinations showed that the severity of prostatic intraepithelial neoplasia and inflammation development gradually increased as PTEN null mice aged. Collectively, these findings suggest that loss of PTEN drives global changes in DNA CpG methylation and transcriptomic gene expression and highly associated with several inflammatory and immune molecular pathways during PCa development. These biomarkers could be valuable molecular targets for cancer drug discovery and development against PCa.